Agenus' BOT+BAL Combination Shows 48% Three-Year Survival in Recurrent Ovarian Cancer
Event summary
- Agenus reported 48% estimated three-year overall survival for its BOT+BAL combination in recurrent ovarian cancer patients, unchanged from the two-year estimate.
- The study included 35 evaluable patients, all of whom had received prior platinum chemotherapy, with 77% having also received bevacizumab and 57% a PARP inhibitor.
- 25% of treated patients (11 of 44) were alive and off all therapy at the last follow-up.
- The results were presented at the 2026 IGCS Annual Global Meeting in Montréal, Canada.
The big picture
Agenus' data suggests that its BOT+BAL combination may offer lasting benefits in recurrent ovarian cancer, a population where conventional immunotherapies have largely failed. The results align with a broader trend of exploring novel immune checkpoint inhibitors to address treatment-resistant cancers. The durability of responses in heavily pretreated patients could position Agenus as a key player in the immuno-oncology space, particularly if these findings hold up in larger, controlled studies.
What we're watching
- Clinical Efficacy
- Whether the durable survival benefits observed in heavily pretreated ovarian cancer patients will translate into earlier-stage settings.
- Regulatory Pathway
- The pace at which Agenus advances BOT+BAL through subsequent clinical trials and potential regulatory filings.
- Market Differentiation
- How Agenus positions BOT+BAL against existing and emerging immuno-oncology therapies in recurrent ovarian cancer.
Related topics
